related documents
- Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis). Conferences
- First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC). Conferences
- Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC). Conferences
- Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC). Conferences
- Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma. Conferences
- Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs). Conferences
- Investigating a novel recombinant antibody to attenuate prostate cancer progression by targeting cell surface GRP78. Conferences
- Mechanisms underlying the association between sarcopenia and poor oncologic outcomes in clear cell renal cell carcinoma. Conferences
- Prostate cancer-derived anti-GRP78 autoantibodies compromise the blood-brain barrier and accelerate atherosclerosis progression in vivo. Conferences
- Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada Conferences
- Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors. Conferences